Skip to content

Low (-4) vs Physiologic (-8) Pressure Digital Continuous Suction After Lung Resection

Efficacy and Safety of Low Pressure (-4cmH2O) Suction Compared With Physiologic Pressure (-8cmH2O) Suction Using Digital Continuous Suction System After Pulmonary Resection: A Prospective Randomized Controlled Open-label Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07527702
Acronym
Suction48
Enrollment
160
Registered
2026-04-14
Start date
2025-09-03
Completion date
2026-06-01
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer Patient

Brief summary

The goal of this clinical trial is to learn whether using a lower negative pressure (-4 cmH₂O) on a digital chest drainage device after lung resection reduces the time a chest tube must stay in place compared with the commonly used physiologic pressure (-8 cmH₂O), without increasing complications. The trial enrolls adult patients undergoing segmentectomy or lobectomy for lung cancer at a tertiary medical center. The main questions it aims to answer are: Does the -4 cmH₂O setting shorten chest tube duration (primary outcome) compared with -8 cmH₂O? What is the effect of -4 vs -8 cmH₂O on air-leak duration, length of hospital stay, and postoperative complications (e.g., pneumothorax, subcutaneous emphysema, re-intervention), and on the need for pleurodesis or suction readjustment, and 30-day readmission? Researchers will compare patients assigned to -4 cmH₂O with patients assigned to -8 cmH₂O to see whether the lower pressure improves recovery after lung resection. The trial is prospective, randomized, open-label (two parallel arms; planned sample size \ 160; 1:1 allocation). An interaction analysis will also explore whether effects differ between patients with lower vs higher air-leak flow on postoperative day (POD) 1. Participants will: Receive standard perioperative care for lung resection. Provide written informed consent on the day before surgery following a discussion with study staff. On POD#1 (approximately 7-8 AM), have air-leak flow measured by the digital device. If no clinically meaningful air leak is present on POD#1 (e.g., 0-10 mL/min by institutional criteria) and the chest tube is likely to be removed, the participant will not be randomized and will continue standard care outside the comparative analysis (screen fail/observational record only). If an air leak persists on POD#1, the participant will be randomized to -4 or -8 cmH₂O suction and the assigned setting will be maintained until chest tube removal, unless a clinical safety reason requires adjustment. Undergo routine inpatient assessments already used in standard care (e.g., daily chest X-rays, recording of air-leak flow and drainage volume, monitoring for complications) until discharge. The study uses a commercially available digital chest drainage system already employed in routine practice. Because it is open-label, neither clinicians nor participants are blinded to the pressure setting. If predefined safety signals occur (e.g., clear increases in complications or prolonged air leaks in one arm), the protocol allows suction adjustment for individual safety and interim review for potential early stopping, in accordance with institutional policies.

Interventions

DEVICELow-pressure digital suction (-4 cmH₂O)

A digital thoracic drainage device set to continuous suction at -4 cmH₂O, initiated on postoperative day 1 after randomization. The assigned suction pressure is maintained until chest tube removal unless predefined clinical safety criteria require adjustment. Air-leak flow and drainage volume are recorded as part of routine postoperative care.

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults ≥19 years of age. * Undergoing anatomical lung resection (segmentectomy or lobectomy) for confirmed or suspected primary lung cancer at a tertiary center. * Digital continuous suction device (Thopaz) used as the sole chest drainage system immediately after surgery. * Able to provide written informed consent on the day before surgery. * Randomization criterion (in-hospital): On postoperative day 1 (approximately 7-8 AM), a measurable air leak persists and the chest tube is not removed per routine care. Participants with no clinically meaningful air leak on POD1 (e.g., 0-10 mL/min per institutional criteria) will be considered screen failures and will not be assigned to an arm.

Exclusion criteria

* Placement of two or more drains (e.g., additional chest tube or JP drain) during the index surgery. * Intraoperative or immediate postoperative serious complication requiring ICU care. * Change from the digital suction system to another drainage system prior to randomization or outcome assessment. * Any condition that, in the opinion of the investigator, makes participation inappropriate (e.g., inability to comply with study procedures or safety concerns).

Design outcomes

Primary

MeasureTime frameDescription
Duration of postoperative air leak (days)Time Frame: From postoperative day 1 randomization to the date of air-leak resolution, assessed daily, up to 30 days postoperatively or until hospital discharge.Daily air-leak flow (mL/min) recorded by the digital chest drainage system (≈6 AM). Air-leak resolution is defined as no visible air leak or \<10 mL/min sustained for ≥12 hours with adequate lung expansion on chest X-ray and stable clinical status. Duration is calculated in days from randomization (POD1) to resolution.

Secondary

MeasureTime frameDescription
Chest tube duration (days)Time Frame: From the date of surgery to the date of chest tube removal, assessed during the index hospitalization for up to 30 postoperative days.Number of calendar days the chest tube remains in place during the index hospitalization.

Countries

South Korea

Contacts

CONTACTSeonYong Bae, MD
bsy115s@naver.com82) + 010-3205-4460

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 15, 2026